<DOC>
	<DOCNO>NCT02868242</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy , safety , tolerability ledipasvir/sofosbuvir ( LDV/SOF ) treat hepatitis C virus ( HCV ) infection pediatric participant undergo cancer chemotherapy .</brief_summary>
	<brief_title>Efficacy Safety Ledipasvir/Sofosbuvir Fixed Dose Combination Treatment Hepatitis C Virus ( HCV ) Infection Pediatric Participants Undergoing Cancer Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<mesh_term>Ledipasvir , sofosbuvir drug combination</mesh_term>
	<criteria>Key Aged 12 &lt; 18 year Parent legal guardian must provide write informed consent Treatment naïve experience child genotype 1 4 HCV infection , maintenance cancer chemotherapy regimen Receiving protocolapproved maintenance chemotherapy regimen hematological malignancy Chronic HCV infection ( ≥ 6 month ) document medical history liver biopsy Screening laboratory value within define threshold No History solid organ bone marrow transplantation No history clinical hepatic decompensation ( eg , ascites , jaundice , encephalopathy , variceal hemorrhage ) NOTE : Other protocol define Inclusion/ Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>HCV genotype 1 4 ( GT-1 GT-4 )</keyword>
	<keyword>Direct Acting Antiviral</keyword>
	<keyword>Combination Therapy</keyword>
	<keyword>Hepatitis C , Chronic</keyword>
	<keyword>Liver Diseases</keyword>
	<keyword>Virus Diseases</keyword>
</DOC>